Comparative Pharmacology
Head-to-head clinical analysis: A METHAPRED versus DECADRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A METHAPRED versus DECADRON.
A-METHAPRED vs DECADRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor and modulating gene expression to produce anti-inflammatory and immunosuppressive effects. It also suppresses adrenal function by inhibiting ACTH secretion.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
0.75-9 mg/day orally in divided doses every 6-12 hours; or 0.5-9 mg/day IM/IV in divided doses every 12 hours for acute conditions; for cerebral edema, IV loading dose of 10 mg followed by 4 mg IM/IV every 6 hours.
None Documented
None Documented
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Terminal half-life: 3-4 hours (plasma); biological half-life: 36-54 hours (due to intracellular receptor binding); clinical context: duration of HPA axis suppression longer than plasma half-life
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Renal (65-80% as 17-hydroxycorticosteroids and 20-hydroxycorticosteroids after hepatic metabolism); biliary/fecal (minor, <10%)
Category C
Category C
Corticosteroid
Corticosteroid